Comerica Bank Buys Shares of 10,000 Annexon, Inc. (NASDAQ:ANNX) (2024)

Comerica Bank purchased a new position in Annexon, Inc. (NASDAQ:ANNX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $72,000.

Several other large investors have also recently made changes to their positions in the company. BVF Inc. IL purchased a new position in Annexon in the 4th quarter valued at $31,780,000. Bain Capital Life Sciences Investors LLC lifted its stake in shares of Annexon by 41.4% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock worth $36,600,000 after buying an additional 2,359,793 shares in the last quarter. Bellevue Group AG purchased a new position in shares of Annexon in the first quarter worth about $15,647,000. Vanguard Group Inc. boosted its position in Annexon by 96.4% during the first quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock worth $26,871,000 after acquiring an additional 1,839,329 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Annexon by 10,482.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,323,704 shares of the company’s stock valued at $9,492,000 after acquiring an additional 1,311,195 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Wednesday, June 5th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Wells Fargo & Company lowered their price objective on Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Annexon in a research note on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon presently has an average rating of “Buy” and a consensus price target of $15.33.

Get Our Latest Stock Analysis on Annexon

Annexon Stock Performance

Shares of Annexon stock opened at $6.10 on Monday. The stock has a 50 day moving average of $5.51 and a 200 day moving average of $5.41. The firm has a market capitalization of $563.72 million, a price-to-earnings ratio of -4.15 and a beta of 1.29. Annexon, Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $8.40.

Annexon (NASDAQ:ANNX – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). Analysts forecast that Annexon, Inc. will post -0.98 EPS for the current year.

Annexon Company Profile

(Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Featured Articles

• Five stocks we like better than Annexon
• CD Calculator: Certificate of Deposit Calculator
• This Small Cap Wealth Management Stock Could Provide Big Returns
• The Significance of Brokerage Rankings in Stock Selection
• Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
• 3 REITs to Buy and Hold for the Long Term
• MarketBeat Week in Review – 8/12 – 8/16

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX – Free Report).

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.